r-hFSH + r-hLH + u-hCG
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility
Conditions
Infertility
Trial Timeline
Dec 1, 1999 → Jul 1, 2001
NCT ID
NCT01735422About r-hFSH + r-hLH + u-hCG
r-hFSH + r-hLH + u-hCG is a phase 2 stage product being developed by Merck for Infertility. The current trial status is completed. This product is registered under clinical trial identifier NCT01735422. Target conditions include Infertility.
What happened to similar drugs?
10 of 20 similar drugs in Infertility were approved
Approved (10) Terminated (4) Active (10)
🔄GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01735422 | Phase 2 | Completed |
Competing Products
20 competing products in Infertility